EGFR and non-small cell lung carcinoma: Most of the published studies were focused on EGFR alterations, which are the most commonly encountered actionable mutations in clinical practice, being present in 40–50% and 10–20% of NSCLC patients of Asian and non-Asian ethnicity, respectively [33,81,82].